End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0622 DKK | +3.67% | +45.33% | +107.33% |
03-29 | Dancann Pharma Plans Up to DKK19 Million Rights Issue | MT |
02-28 | DanCann Pharma Notes Cannabis Legalization in Germany as Shares Surge | MT |
Valuation
Fiscal Period: December | 2020 | 2021 | 2022 |
---|---|---|---|
Capitalization 1 | 66.75 | 175.2 | 37.06 |
Enterprise Value (EV) 1 | 45.61 | 167.5 | 26.31 |
P/E ratio | -6.71 x | -12.7 x | -2.31 x |
Yield | - | - | - |
Capitalization / Revenue | -13.8 x | 200 x | 5.15 x |
EV / Revenue | -9.44 x | 192 x | 3.66 x |
EV / EBITDA | -7.9 x | -12.3 x | -1.85 x |
EV / FCF | -1,584,675 x | -5,222,178 x | -1,496,042 x |
FCF Yield | -0% | -0% | -0% |
Price to Book | 1.51 x | 3.28 x | 0.59 x |
Nbr of stocks (in thousands) | 20,731 | 26,551 | 65,015 |
Reference price 2 | 3.220 | 6.600 | 0.5700 |
Announcement Date | 21-04-07 | 22-04-12 | 23-05-12 |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 |
---|---|---|---|---|
Net sales 1 | -0.4218 | -4.83 | 0.874 | 7.189 |
EBITDA 1 | -0.6189 | -5.776 | -13.62 | -14.19 |
EBIT 1 | -0.6268 | -5.87 | -14.51 | -16.42 |
Operating Margin | 148.6% | 121.55% | -1,659.95% | -228.38% |
Earnings before Tax (EBT) 1 | -0.6384 | -5.986 | -15.18 | -18.25 |
Net income 1 | -0.4998 | -4.255 | -11.75 | -16.06 |
Net margin | 118.5% | 88.09% | -1,344.39% | -223.45% |
EPS | - | -0.4801 | -0.5200 | -0.2471 |
Free Cash Flow | - | -28.78 | -32.07 | -17.58 |
FCF margin | - | 595.93% | -3,669.89% | -244.6% |
FCF Conversion (EBITDA) | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - |
Dividend per Share | - | - | - | - |
Announcement Date | 21-04-07 | 21-04-07 | 22-04-12 | 23-05-12 |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2022 Q1 | 2023 Q1 |
---|---|---|
Net sales 1 | 1.266 | 0.62 |
EBITDA | - | - |
EBIT | - | - |
Operating Margin | - | - |
Earnings before Tax (EBT) | - | - |
Net income | - | - |
Net margin | - | - |
EPS 2 | -0.0100 | -0.0500 |
Dividend per Share | - | - |
Announcement Date | 22-05-18 | 23-05-31 |
Balance Sheet Analysis
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 |
---|---|---|---|---|
Net Debt 1 | - | - | - | - |
Net Cash position 1 | 0.18 | 21.1 | 7.74 | 10.8 |
Leverage (Debt/EBITDA) | - | - | - | - |
Free Cash Flow | - | -28.8 | -32.1 | -17.6 |
ROE (net income / shareholders' equity) | - | -19.5% | -24.1% | -27.7% |
ROA (Net income/ Total Assets) | - | -14.4% | -15.3% | -14.4% |
Assets 1 | - | 29.58 | 76.81 | 111.7 |
Book Value Per Share | - | 2.140 | 2.010 | 0.9700 |
Cash Flow per Share | - | 1.030 | 0.2900 | 0.1700 |
Capex 1 | 0.06 | 4.02 | 6.37 | 1.01 |
Capex / Sales | -14.62% | -83.14% | 728.83% | 13.99% |
Announcement Date | 21-04-07 | 21-04-07 | 22-04-12 | 23-05-12 |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+107.33% | 1.43M | |
-1.65% | 104B | |
+6.75% | 97.47B | |
+5.71% | 22.25B | |
-12.60% | 21.68B | |
-9.70% | 18.2B | |
-39.98% | 17.02B | |
-10.17% | 16.36B | |
+6.12% | 14.39B | |
+35.47% | 12.37B |
- Stock Market
- Equities
- DANCAN Stock
- Financials Dancann Pharma A/S